Altimmune announces early completion of enrollment in RECLAIM Phase 2 trial

Altimmune (ALT) announced the completion of patient enrollment in RECLAIM, a Phase 2 clinical trial evaluating pemvidutide in adults with alcohol use disorder, AUD. The trial is evaluating pemvidutide in approximately 100 patients across sites in the U.S. Altimmune expects to announce topline results from the trial in 2026. “We are thrilled to have completed enrollment in our RECLAIM trial several months ahead of schedule, signaling strong enthusiasm from both patients and physicians to explore new treatment options for AUD. Pemvidutide has the potential to be a substantial therapeutic advance for these patients in one of the largest known areas of unmet need,” said Christophe Arbet-Engels, M.D., Ph.D., Chief Medical Officer of Altimmune. “The unique dual agonism of pemvidutide could not only target cravings and overall alcohol consumption but may address alcohol-related fatty liver damage, which can lead to liver inflammation and progression to alcohol-associated liver disease. We look forward to sharing results from the trial in the year ahead, and in the meantime we anticipate sharing 48-week results from the IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis later this quarter.”